LMI Aerospace, Inc. (NASDAQ:LMIA), announced that long-time director Joseph Burstein retired from the Board, effective March 6, and Steven Schaffer has been appointed to fill the vacancy, effective April 1. On Tuesday shares of LMI Aerospace Inc. (NASDAQ:LMIA) closed at $12.09. Company’s sales growth for last 5 years was 11.50% and EPS growth for next 5 years is recorded as 15.00%.
Transgenomic, Inc. (NASDAQ:TBIO), announced that it has signed an amended license agreement with Exiqon A/S for the expansion of rights to their proprietary Locked Nucleic Acid (LNA™) oligonucleotides, which offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides Transgenomic with access to LNA oligos for use with all of the company’s proprietary ultra-high sensitivity mutation enrichment technologies, including its Multiplexed ICE COLD-PCRTM (MX-ICP). Transgenomic Inc. (NASDAQ:TBIO) in last trading activity fell -4.91% to close at $1.55. Company weekly performance is -8.82% while its quarterly performance stands at -6.06%. Transgenomic Inc. (NASDAQ:TBIO) is -73.04% away from its 52 week high.
On last trading day The Medicines Company (NASDAQ:MDCO) increased 0.70% to close at $27.35. Its volatility for the week is 4.50% while volatility for the month is 3.55%. MDCO’s sales growth for past 5 years was 12.40% and its EPS growth for past 5 years was 19.30%. The Medicines Company (NASDAQ:MDCO) monthly performance is -3.49%.
On March 2, LSI Industries Inc. (NASDAQ:LYTS) announced the appointment of Andrew J. Foerster to the position of Executive Vice President and Chief Technology Officer, effective March 2, 2015. Mr. Foerster received a Bachelor of Science, Electrical Engineering from the U.S. Naval Academy; a Master’s Degree in Electrical Engineering from George Mason University; and an MBA from Marymount University. He is a licensed Professional Engineer. LSI Industries Inc. (NASDAQ:LYTS) has 5.40% insider ownership while its institutional ownership stands at 62.10%. In last trading activity company’s stock closed at $7.69.
MLV & Costarted coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Tuesday. The firm set a “buy” rating and a $26.00 price target on the stock. MLV & Co‘s target price points to a potential upside of 160.00% from the company’s current price. On last trading day Cara Therapeutics Inc. (NASDAQ:CARA) fell -2.37% to close at $9.87. Its volatility for the week is 4.03% while volatility for the month is 3.44%. Cara Therapeutics Inc. (NASDAQ:CARA) monthly performance is -9.28%.